Dear shareholders and friends,
U.S. Stem Cell Inc. continues to innovate and grow, making our mark in the regenerative medicine field by developing a number of therapies and products for patients suffering from degenerative conditions. Our three main operating divisions (U.S. Stem Cell Training, VetBiologics, and U.S. Stem Cell Clinic), focus on the development and commercialization of cell-based therapies that repair and replace damaged tissues, cells, and organs, restoring them to their normal functions.
Because of our dedication to the field, we have been able to help patients who previously had very few options available to them. We have had success helping patients with degenerative conditions, markedly demonstrated in our Traumatic Brain Injury patients who’ve shown great results. We have not only been able to treat thousands of patients, but also have been actively involved in training physicians in our field, and have made meaningful contributions to international guidelines for stem cell research.
All of this would not be possible without our shareholders, partners, and dedicated team of practitioners. I would like to personally thank you all for your invaluable contributions and on-going support.
This month, we are pleased to announce a number of new developments.
We have recently launched our brand new website, which we hope will clearly guide you through the work that we do. This is part of our dedication to keeping you fully informed about our business operations and our continuing innovations in the field of stem cell research. Navigate through to learn about our products, board members, company news, financial summaries, and much more.
Our business strives to make its operations as efficient and cost effective as possible. In the most recent quarter, our company has succeeded in reducing its expenditures in operational activities, general and administrative tasks, and marketing strategies. An increase in banking services has meant that our Gross Margin from 2014 and 2015 has decreased. Despite this fact, we have seen a growth in revenue, as well as an improvement in our capital deficit, net loss, and current liabilities.
A summary of U.S. Stem Cell’s most recent financial figures through 4th quarter 2015:
Reductions in expenditure
- Cash used in Q4 2015 down 85% or $306K.
- From $361K in Q4 2014 to $55K in Q4 2015
- Cash used in operating activities down $255k or 24%.
- From $1.1M in 2014 to $845k in 2015
- Marketing, general, and administrative expenses down $1.4M or 28.9%
- From $4.7M in 2014 to $3.3M in 2015
General improvements
- Current liabilities down by $3.1 million or 28%
- From $11.1M in 2014 to $8.0M in 2015
- Working capital deficit improved by $4.4 million or 40%
- From $10,957,443 in 2014 to $6,583,569 in 2015
Profits and losses
- Revenue up by 8%
- From $2.06M in 2014 to $2.2M in 2015
- Net loss improved 26% from $2.3M in 2014 to $1.7M in 2015
- Gain on debt in 2014 of $2.5M, compared to gain of debt of $2.6M in 2015
- Gross Margin down from 58.9% in 2014 to 32.9% in 2015, primarily due to increase in banking service
We invite you to follow us on social media for the latest updates and information about U.S. Stem Cell.
Warm Regards,
Mike Tomas
President & CEO
The information provided above is not be relied upon for the purchase or sale of our securities. Please see our filings with the Securities and Exchange Commission (found at sec.gov). In addition, this release is for informational purposes only and is not an offer to purchase or sell any of our securities. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2015, and its Quarterly Reports on Form 10-Q.